deltatrials
Unknown PHASE2 INTERVENTIONAL 3-arm NCT03267654

Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance

Gefitinib Versus Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance：A Randomized, Multicentre, Phase II Study

Sponsor: Qilu Pharmaceutical Co., Ltd.

Conditions Non-small-cell Lung Cancer
Interventions gefitinib combined with apatinib gefitinib combined with chemotherapy gefitinib single agent
Updated 9 times since 2017 Last updated: Jul 31, 2020 Started: Oct 12, 2017 Primary completion: Oct 20, 2020 Completion: Dec 30, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small-cell Lung Cancer and is currently ongoing. Qilu Pharmaceutical Co., Ltd. leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotNot Yet Recruiting~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshotNot Yet Recruiting~Sep 2018 – ~Sep 2019 · 12 months · monthly snapshotRecruiting~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshotUnknown Status~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotRecruiting~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshotRecruiting~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Sep 2022 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Jan 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    Status: Unknown Status → Recruiting

▶ Show 4 earlier versions

  1. Sep 2019 — Sep 2020 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  2. Sep 2018 — Sep 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Jun 2018 — Sep 2018 [monthly]

    Not Yet Recruiting PHASE2

  4. Sep 2017 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Qilu Pharmaceutical Co., Ltd.
Data source: Qilu Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations